Milford Funds Ltd. Invests $32.09 Million in IQVIA Holdings Inc. $IQV

Milford Funds Ltd. acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 142,348 shares of the medical research company’s stock, valued at approximately $32,087,000.

Other hedge funds also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA during the fourth quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA during the fourth quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at $27,000. Activest Wealth Management increased its position in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new stake in IQVIA during the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IQV shares. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Morgan Stanley set a $225.00 target price on IQVIA in a research report on Thursday, May 7th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. HSBC set a $210.00 price target on IQVIA in a research report on Wednesday, June 3rd. Finally, Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Stock Performance

NYSE IQV opened at $181.10 on Friday. The firm has a market cap of $30.23 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 1.55 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50-day moving average price of $173.56 and a 200-day moving average price of $193.68. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.